Your session is about to expire
← Back to Search
Screening Strategies for Coronary Artery Disease in Kidney Transplant Candidates (CARSK Trial)
N/A
Recruiting
Led By Jagbir Gill, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the analysis will take place at the end of the study. this outcome will be followed up for 5 years.
Awards & highlights
CARSK Trial Summary
This trial will test if eliminating regular use of non-invasive screening tests for CAD after waitlist activation is not worse than regular screening during wait-listing.
Who is the study for?
This trial is for adults over 18 with dialysis-dependent kidney failure who are being assessed for or on the waiting list for a kidney transplant. They must need further heart disease screening and expect to undergo transplantation more than a year after joining the study. Those with other organ transplants, uncontrolled cardiac issues, or unable to consent are excluded.Check my eligibility
What is being tested?
The CARSK trial is examining if not regularly using non-invasive tests to check for coronary artery disease in kidney transplant candidates is as effective as annual screenings in preventing major heart problems. It also looks at how screening affects transplant rates and its cost-effectiveness.See study design
What are the potential side effects?
Since this trial involves no direct medical interventions but compares different frequencies of screening procedures, there are no side effects associated with medications or treatments. However, potential risks may include those related to undergoing diagnostic procedures.
CARSK Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ the analysis will take place at the end of the study. this outcome will be followed up for 5 years.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the analysis will take place at the end of the study. this outcome will be followed up for 5 years.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
MACE
Secondary outcome measures
All-cause death
Cancellation of transplantation due to coronary artery disease
Cardiovascular death
+7 moreCARSK Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: No screeningExperimental Treatment1 Intervention
No further screening for asymptomatic coronary artery disease after wait-list entry
Group II: Regular screeningActive Control1 Intervention
Regular (yearly or 2nd yearly) screening for asymptomatic coronary artery disease after wait-list entry
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,418 Previous Clinical Trials
2,463,812 Total Patients Enrolled
University of SydneyOTHER
190 Previous Clinical Trials
211,426 Total Patients Enrolled
Jagbir Gill, MDPrincipal InvestigatorUniversity of British Columbia
1 Previous Clinical Trials
30 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have had a transplant of a different organ.You are scheduled to receive an organ from a living donor.You need dialysis for kidney failure or are waiting for a kidney transplant.You are 18 years old or older.You may need to be checked for heart disease before getting a transplant, as per usual medical practice.You are expected to have a transplant more than 12 months from the start of the study.You have symptoms of serious heart problems that are not being controlled.You are not able to have a transplant because of a medical issue.You are waiting for a transplant involving multiple organs, like a kidney and pancreas.
Research Study Groups:
This trial has the following groups:- Group 1: No screening
- Group 2: Regular screening
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are people able to enroll in this experiment at the present time?
"Affirmative. According to the clinicaltrials.gov portal, this medical trial is enlisting patients and has been since December 1st of 2018 when it was first published. The most recent update occurred on November 4th 2022; 3306 people from 16 locations are needed for enrollment."
Answered by AI
How many locales are currently hosting this clinical investigation?
"In order to fill the quota of participants, this trial is recruiting at The George Washington University in Washington D.C., University Health Network in Toronto, as well as the University of British Columbia in Vancouver and an additional 16 sites."
Answered by AI
What is the aggregate tally of participants in this medical study?
"In order to meet the desired enrollment goals, 3306 participants that match the inclusion criteria must join this trial. These individuals can sign-up at The George Washington University in Washington D.C., or University Health Network in Toronto, Ontario."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger